Acute Myeloid Leukemia Trial Progress Reported
The Regal study for acute myeloid leukemia patients nears its final data analysis threshold.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Do you trust the long-term potential of speculative biotech stocks for your investment portfolio?
Sellas Life Sciences has reached 78 of the 80 required events for its Phase 3 Regal trial in acute myeloid leukemia. This trial milestone, which remains ongoing, is currently the focus of investor attention regarding treatment outcomes.
Why it matters
Understanding survival benchmarks for acute myeloid leukemia is essential for patients and clinicians evaluating current standard-of-care options. Research comparing therapies, such as Venetoclax-based approaches, informs expectations for future treatment progress.
A study of 2,610 acute myeloid leukemia patients compared therapeutic interventions, finding a median survival of 11.4 months for those receiving Venetoclax-based therapy versus 8.2 months for those on hypomethylating drugs alone.
The players
Sellas Life Sciences
A biopharmaceutical company focused on the development of novel cancer immunotherapies for hematological malignancies.
The details
The Regal trial process requires a total of 80 patient events to trigger a database lock and initiate a blinded data review. By comparing survival metrics like those observed in recent large-cohort studies, researchers seek to determine how new interventions improve outcomes for individuals currently managed with standard hypomethylating agents.
Timeline
May 11, 2026: Sellas reported 78 events for the Regal trial.
August 2026: The company confirmed the process for announcing the 80th event.
October 7, 2026: The stock price closed at $11.31 following a 0.3 percent daily decline.
Q4 2026: Topline data is expected for the SLS009 Phase 2 trial.
Health Landscape
The Regal Phase 3 trial represents an effort to refine therapeutic benchmarks for acute myeloid leukemia. This research follows established patterns in oncology where large-scale patient analysis is used to set survival goals for emerging pharmaceutical interventions.
Patients with acute myeloid leukemia should discuss the current standard of care and ongoing research trials with their oncology team. It is worth asking your physician about how survival data from recent studies might apply to your specific treatment plan.
The takeaway
Clinical trials are fundamental to establishing improved survival benchmarks for patients with acute myeloid leukemia. Consult your healthcare provider to understand how trial results and emerging therapies relate to your specific diagnosis and care options.
Further reading
For more on the current research landscape, see our comprehensive coverage on Cancer.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you trust the long-term potential of speculative biotech stocks for your investment portfolio?
